Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Georges Nakhoul

ResearcherPublications, citations & collaboration network

Georges Nakhoul is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 99 works, 1,338 citations, an h-index of 18 and an i10-index of 24.

99
Works
1,338
Citations
18
h-index
24
i10-index

How has Georges Nakhoul's publication output changed over time?

ScholarIQpublication output · 2015–2025

Output grew0% over the shown period — from 1 works in 2015 to 1 in 2025.

1
2
1
1
1
2
2
1
20152016201720182019202220232025

What are the most-cited papers on Georges Nakhoul?

ScholarIQmost cited works
Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease
Georges Nakhoul, Haiquan Huang, Susana Arrigain, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally, Sankar D. Navaneethan
American Journal of Nephrology. 2015167 CitationsOPEN ACCESS
Geographic Trends, Patient Characteristics, and Outcomes of Infective Endocarditis Associated With Drug Abuse in the United States From 2002 to 2016
Amer N. Kadri, Bryan Wilner, Adrían V. Hernández, Georges Nakhoul, Johnny Chahine, Brian P. Griffin, Gösta Pettersson, Richard A. Grimm, José Navia, Steven M. Gordon, Samir Kapadia, Serge C. Harb
Journal of the American Heart Association. 2019149 CitationsOPEN ACCESS
Therapeutic Advances in Diabetic Nephropathy
Hanny Sawaf, George Thomas, Jonathan J. Taliercio, Georges Nakhoul, Tushar J. Vachharajani, Ali Mehdi
Journal of Clinical Medicine. 2022119 CitationsOPEN ACCESS
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
PK Judge, Natalie Staplin, KJ Mayne, Christoph Wanner, Julie Green, SJ Hauske, Jonathan Emberson, David Preiss, SYA Ng, AJ Roddick, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, Susanne Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Daisy Massey, Martin Landray, Colin Baigent, Richard Haynes, WG Herrington, S Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masanori Abe, Nader G. Abraham, Sarah Acheampong, P Achiri, JA Acosta, A. Q. Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Movahedian Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, A. Aitken, R AitSadi, Sendogan Aker, S Akimoto, A Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Leslie N. Aldrich, M Alegata, Lee Alexander, S Alfaress, Mohammad Alhadj Ali, Ahmed Issam Ali, Ahmed Issam Ali, Radica Z. Alicic, A Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, Mora Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, Kwame Ansu, A Apostolidi
The Lancet Diabetes & Endocrinology. 2023116 CitationsOPEN ACCESS
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner, Julie Green, Jonathan Emberson, David Preiss, KJ Mayne, SYA Ng, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, S Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Siegfried Seidi, Martin Landray, Colin Baigent, WG Herrington, Sharirose Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masami Abe, Ned Abraham, Sarah Acheampong, P Achiri, JA Acosta, A A Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, Alastair Aitken, R AitSadi, Sendogan Aker, S Akimoto, Akinwande A. Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Luke Aldrich, M Alegata, Lacy M. Alexander, S Alfaress, Mohammad Alhadj Ali, A Ali, A Ali, Radica Z. Alicic, Arta Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, M. Ochoa de Olza Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, K Ansu, A Apostolidi, N. Arai
The Lancet Diabetes & Endocrinology. 202394 CitationsOPEN ACCESS

Related on ScholarIQ

Cleveland Clinic
Institution
Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease
Paper
Geographic Trends, Patient Characteristics, and Outcomes of Infective Endocarditis Associated With Drug Abuse in the United States From 2002 to 2016
Paper
Therapeutic Advances in Diabetic Nephropathy
Paper
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
Paper
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Paper
470M+ articles · free account